Equibles does not estimate personal net worth.
Earlier roles on record: CFO at Pulse Biosciences, Inc. (PLSE) until November 30, 2022. Pulse Biosciences, Inc. reported in an 8-K filed December 6, 2022 that Sandra Gardiner resigned as Chief Financial Officer, effective November 30, 2022. The proxy statement of Pulse Biosciences, Inc. reports total compensation of $2,097,566 for Sandra Gardiner in fiscal 2019, including a base salary of $50,000. Sandra Gardiner has spoken on 11 earnings calls across 1 company, most recently for Pulse Biosciences, Inc. on November 10, 2022. The companies whose calls Sandra Gardiner spoke on are classified in the Healthcare sector.
“On November 30, 2022, Sandra Gardiner, the Chief Financial Officer of Pulse Biosciences, Inc. (the "Company") gave notice that she was resigning from the Company.”
“Given our shift in focus to advance NPS technology outside dermatology, there was no revenue recognized in the third quarter of 2022. Moving down the income statement, I’ll focus my comments on our non-GAAP results.”
“Our second quarter results reflect the initial benefits of the restructuring plan we announced at the end of Q1. These decisions were made to reduce our operating expenses, preserve financial resources, and focus our near-term sales and marketing efforts on increasing utilization of the CellFX Systems.”
“On March 31, 2022, we announced and implemented a restructuring plan to reduce our operating expenses, preserve financial resources, and focus sales and marketing efforts on increasing utilization of the CellFX System.”
“For the fourth quarter of 2021, revenue was $844,000. Revenue was driven by the conversion of 17 control launch participants opting to purchase their CellFX Systems following completion of the program, as well as the first two commercial sales of the CellFX System.”
“As Darrin mentioned, in the third quarter, we recorded our first revenue as a company. For the third quarter of 2021, revenue was $574,000. Revenue was driven by the conversion of 12 controlled launch participants opting to purchase their CellFX Systems following completion of the program.”
Start not stated–2022-11-30
Medical Instruments & Supplies · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Pulse Biosciences, Inc. (PLSE) | Executive Vice President, Finance and Administration and Chief Financial Officer | $50,000 | $2,097,566 |
